Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Evaluation of the antimycobacterial activity of crude extracts and solvent fractions of selected Ethiopian medicinal plants

BMC Complementary and Alternative Medicine volume 17, Article number: 143 (2017) Cite this article

Abstract

Background

Tuberculosis (TB) is a global health problem complicated by drug resistance and human immunodeficiency virus that has dramatically increased active TB. Several medicinal plants are used traditionally to treat TB in Ethiopia and investigating these plants is required as plants are an alternative source for development of new anti-TB drugs. The purpose of this study was to investigate antimycobacterial activity of crude extract of Carissa edulis, Otostegia integrifolia, Persea americana, Pterolobium stellatum and Vernonia amygdalina as well as fractions of the most active crude extract.

Methods

The effect of various doses of the crude extracts as well as solvent fractions on M. tuberculosis H37Rv and/or MDR-TB clinical isolate was determined using broth microdilution and microtiter resazurin assay methods. Minimum inhibitory concentration was determined by CFU count and resazurin color change observation.

Results

Chloroform and 80% methanol extracts of P. stellatum and O. integrifolia as well as 80% methanol and acetone extracts of P. americana had significant antimycobacterial activity (p < 0.001) against M. tuberculosis H37Rv. Chloroform extract of V. amygdalina and C. edulis didn’t, however, show any significant activity compared to negative controls. P. stellatum chloroform extract was the most active on M. tuberculosis H37Rv (MIC 0.039 mg/ml) and AOZ8W-4 (MDR-TB clinical isolate) (MIC = 0.078 mg/ml). Ethyl acetate fraction of P. stellatum chloroform extract was the most active fraction.

Conclusion

P. stellatum, O. integrifolia and P. americana were found to be endowed with antimycobacterial activity. However, P. stellatum appears to be the most promising plant based on criteria set by different studies. Ethyl acetate fraction of P. stellatum was found to be the most active and future studies should involve this fraction.

Peer Review reports

Background

Mycobacterium tuberculosis, an obligate aerobe belonging to the M. tuberculosis complex (also include M. bovis, M. africanum and M. microti), is the most important cause of TB in humans. In addition to M. tuberculosis complex, Mycobacterium avium complex (include M. avium, M. intracellularae, and M. kansasii) can also cause closely related mycobacterium diseases in AIDS patients and is difficult to distinguish as a group clinically [1].

In 1993, during the world TB day, WHO declared TB as a ‘global emergency,’ which requires emergency action and launched several programs to combat the disease, including the search for newer remedies and/or anti-TB agents to complement currently used agents [2]. In the year 2014, TB killed 1.5 million people (1.1 million HIV-negative and 0.4 million HIV-positive) and 9.6 million new cases of active tuberculosis globally caused by TB [3].

Mycobacteria are slow growing organisms that require administration of a combination of drugs for extended periods to achieve effective therapy and to prevent the emergence of resistance. The risk of adverse reactions therefore must be a major consideration in drug selection. Apart from significant toxicity, lengthy therapy also creates poor patient compliance. Non-compliance is a frequent cause of a deadly multidrug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB). Drug toxicity coupled with the problem of mycobacterial persistence highlights the need to develop novel TB drugs that are active against drug resistant bacteria and kill persistent bacteria as well as shorten the length of TB treatment [4].

Natural products, either as pure compounds or as standardized plant extracts, provide unlimited opportunities for new drug leads because of the unmatched availability of chemical diversity [5]. Scientific interest in medicinal plant has grown in recent times because natural products are evolutionary shaped drugs or drug‐like molecules. Nature’s biosynthetic machinery produces innumerate natural products with distinct biological properties that make them valuable as inhibitors or promoters of biological action [4, 6]. Moreover, higher plant extracts have been considered as promising sources of novel anti-TB leads [7]. This has prompted us to investigate selected Ethiopian medicinal plants, including Carissa edulis Vahl (Apocynaceae), Otostegia integrifolia Benth (Lamiaceae (Labiatae)), Persea Americana Mill (Lauraceae), Pterolobium stellatum (Forsk.) Brenan. (Fabaceae), and Vernonia amygdalina Del. (Asteraceae) for possible anti-TB activity. The plants have been traditionally used to treat respiratory or lung-related diseases, including TB for a very long time [8–11]. The present study attempted to screen the antmycobacterial activity of different solvent extract of these five Ethiopian medicinal plants, and Pterolobium stellatum was found to be the most promising plant for further investigation.

Methods

Plant collection

The roots of O. integrifolia, P. stellatum, and C. edulis were collected from an area near Angereb River, Gondar town, North West Ethiopia, about 730 km away from the capital, Addis Ababa. The root of V. amygdalina and the leaves of P. americana were collected from Bure town, North West Ethiopia, about 400 km far from Addis Ababa. The plants were authenticated by a taxonomist (Mr. Melaku Wondafrash) and a voucher specimen of each plant material was deposited at the National Herbarium, College of Natural and Computational Sciences, Addis Ababa University for future reference with voucher numbers Wk001, WK002, WK003, WK004 and WK005 for O. integrifolia, P. stellatum, C. edulis, V. amygdalina and P. americana, respectively. The plants were cleaned from dirt and soil and dried under shade for two weeks. The plants were spread out and regularly turned over to avoid fermenting and rotting. The dried root parts of plants were grinded using 0.75 mm sieve size hammer type mill, while the dried leaves were pulverized using a wooden mortar and pestle. The powdered material was weighed using an analytical balance and stored at room temperature.

Experimental animals

Swiss albino nulliparous and non-pregnant female mice weighing 31–36 g, and age 8–12 weeks were obtained from the Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University. All animals were housed in an air-conditioned room and allowed to acclimatize for one week before commencement of the study. All the experiments were conducted in accordance with internationally accepted laboratory animal use, care and guideline [12] and the study was approved by the School of Pharmacy Ethics Committee (Protocol number was 042/12/pharmacy). Before and during the experiment, mice were allowed free access to standard pellets and water ad libitum.

Bacterial strains and inoculums preparation

Bacterial cells were M. tuberculosis H37Rv (ATCC no 27294, Manassas, VA) and three MDR-TB clinical isolate strains. The three MDR-TB clinical isolates were AOA8W-4, AOZ8W-4 and SO38SW-4. M. tuberculosis and MDR-TB strains were cultured and grown on Mycobacteria 7H11 medium following procedures described elsewhere [13]. The inoculum was then prepared by diluting cultures at 1/1000 by adding 25 μl cell culture to 25 ml medium, 7H9 broth (4.7 g of Middlebrook 7H9 broth base [Difco - Becton Diskinson], 2 ml of glycerol in 900 ml water) enriched with ADC when cooled to 47 °C [13].

Extraction of plant materials

Crude extract

The air-dried, powdered roots of P. stellatum, O. integrifolia, C. edulis and V. amygdalina were exhaustively extracted with chloroform using maceration technique, while P. americana powdered leaves were extracted with acetone. Up on using chloroform and acetone solvents, maceration was carried out using one liter of the respective solvent for 72 h, with regular shaking. The mixture was filtered with Whatman No. 42 filter paper and the filtrate was kept at + 4°c. The marc was macerated again in the same solvent two times and filtered. The filtrates were combined evaporated under reduced pressure on a rotary evaporator (Buchi Rota Vapor R-200) and dried in oven at 40°c (Gallenkamp, England).

In parallel, the air-dried and powdered roots of P. stellatum, O. integrifolia and powdered leaves of P. americana were Soxhlet extracted with 80% methanol (4:1, methanol: water). The obtained extracts were filtered and evaporated under reduced pressure on a rotary evaporator and lyophilized. The extracts were kept refrigerated and away from light. Stock solutions of all extracts were prepared in DMSO at a concentration of 50 mg/ml and stored at −20 °C until use.

Fractionation

Antimycobacterial activity evaluation of the crude extract revealed P. stellatum chloroform root extract to have a better activity and further fractionation was pursued using this plant. The dried extract (8 g) was suspended in distilled water (200 ml) and then successively partitioned with n-hexane and ethyl acetate in a separatory funnel. The n-hexane and ethyl acetate fractions were concentrated under reduced pressure using rotary evaporator (Buchi Rota Vapor R-200) and dried in an oven under 40 °C, while the water fraction was dried using freeze drier.

Acute oral toxicity test

As no toxicity data was available for any part of P. stellatum chloroform extract, oral toxicity study was conducted using Organization for Economic Cooperation and Development (OECD) guidelines 423 [14]. Briefly, nine mice were randomly divided into three groups of three mice per cage. Before administration of single dose of the extract, the mice were fasted for 3 h and weighed. After administration of a single dose of extract, mice were fasted for 1 h. The first group was given solvent (5% DMSO in distilled water), while the second group were given 2 g/kg (dissolved in 5% DMSO) of the chloroform root extract of P. stellatum orally. The mice in the third group were provided with P. stellatum root extract 5 g/kg dissolved in 5% DMSO after following the first two groups for 14 days. The mice were observed continuously for 1 h after administration of the extract; intermittently for 4 h, over a period of 24 h, and then frequently for 24 h for 14 days. Gross behavioral changes such as loss of appetite, hair erection, lacrimation, tremors, convulsions, salivation, diarrhea, mortality and other signs of toxicity manifestation were observed.

In vitro antimycobacterial assay

Colony count assay

The antimycobacterial effect of the extracts was evaluated at concentrations ranging from 0.00244 mg/ml to 2.5 mg/ml. The test concentrations of the extracts were selected based on cytotoxicity test results in previous studies [4, 10, 15, 16]. Serial two-fold dilution of extracts was made in microtiter wells. Colony forming units (CFUs) were counted from triplicate dilutions and duplicate plates were used for each concentration of test extract and controls. The average CFUs were determined from three independent experiments. The percentage inhibition of growth was determined by dividing the CFUs of the test concentration by the CFUs of the negative control (solvent).

Each extract reconstituted with DMSO (50 mg/ml) was further diluted (5 mg/ml) with Middlebrook 7H9 broth supplemented with Middlebrook ADC. Activity was then measured and MIC was determined for the extracts as well as positive and negative controls following a method described elsewhere [13, 17]. The MIC was the concentration of extract at which 100% inhibition of mycobacterial growth was observed when compared with the growth control.

Resazurin indicator assay

M. tuberculosis H37Rv and clinical isolates of MDR-TB were cultured in Middlebrook 7H9 broth at 37 °C for two weeks in order to reach logarithmic phase growth. Test inoculums were prepared using a procedure described by Patricia and colleagues [18]. After incubation at 37 °C for 7 days, 15 μl of 0.01% resazurin solution in sterile water was added to the first growth control wells and incubated for 24 h. Once the first sets of growth controls turned pink, the dye solution was added to the second set of growth controls and the test wells, incubated for 24 h at 37 °C. Blue color in the wells containing the test compounds would indicate inhibition of growth, while pink indicates lack of inhibition of growth of M. tuberculosis [19]. MIC value was expressed as the lowest concentration of compound that caused 100% inhibition of mycobacterium growth [18]. All assays were run in triplicate and isoniazid was used as positive and DMSO as negative control.

Statistical analysis

Data are expressed as mean ± standard error of mean as appropriate and Statistical analysis of all results was done using the Statistica 10 and GraphPad Prism 5 software. Analysis was done using one-way ANOVA followed by Duncan post hoc test. Level of statistical significance was set at α < 0.05.

Results

Information pertaining the preparation of the crude extracts is depicted in Table 1.

Table 1 Outcome of extraction in the preparation of crude extracts
Full size table

Acute oral toxicity test

Acute oral administration of the chloroform extract of P. stellatum at different doses showed no overt signs of distress for the 14-day observation period. Moreover, there were no observable symptoms of toxicity or deaths even at a dose of 5 g/kg. This indicates that the oral LD50 was greater than 5 g/kg. All treatment and control group mice gained weight and no significant changes in behavior was noted, suggesting that administration of the crude extract had negligible level of toxicity on growth of the animals. In addition, gross behavioral changes such as loss of appetite, hair erection, lacrimation, tremors, convulsions, salivation, diarrhea, mortality and other signs of toxicity manifestations were not observed.

Antimycobacterial activity testing using CFU method

Good growth of M. tuberculosis H37Rv was evident in the microtiter plate wells containing only liquid Middlebrook 7H9 medium and in the universal Petri dishes containing solid Mycobacteria 7H11 medium, within three to four weeks. DMSO control at 2.5 to 0.0024%, equivalent to solvent concentrations in test extracts, exhibited no inhibitory effect on mycobacterial growth as evidenced by higher CFU/ml (Table 2). Among the different concentrations of isoniazid used, total inhibition of growth of mycobacteria was observed at a concentration of 0.125 μg/ml.

Table 2 Antimycobacterial activity of experimental plants using colony count method
Full size table

Extracts showed differential effects on the proliferation of Mycobacterium tuberculosis. The chloroform extract of P. stellatum appeared to be the most active as growth was totally inhibited at concentrations as low as 0.039 mg/ml. Concentrations more than 0.3 mg/ml were required to bring about no growth with the 80% methanol extract of P. stellatum and O. integrifolia as well as with the chloroform extract of O. integrifolia. For the rest of the extracts, increasing concentrations (>1 mg/ml) were associated with growth arrest (Table 2).

The chloroform and 80% methanol extracts of P. stellatum and O. integrifolia as well as 80% methanol and acetone extracts of P. americana had significant antimycobacterial activity (α < 0.001) against M. tuberculosis H37Rv compared to vehicle treated group. By contrast, V. amygdalina and C. edulis chloroform extracts did not have any detectable effect. It is interesting to note that although there was complete inhibition of growth of M. tuberculosis H37Rv at concentrations greater than 1.25 mg/ml for V. amygdalina and C. edulis chloroform extracts, the difference failed to reach statistical significance (Table 2).

Activity testing of crude extract on clinical isolates using Resazurin indicator method

As the chloroform extract of P. stellatum demonstrated the highest activity (MIC = 0.039 mg/ml) against the standard strain in the CFU method, screening of the activity of this extract against clinical isolates of MDR-TB was carried out using resazurin indicator method. The resazurin assay results are depicted in Table 3. Color readings of the growth control wells were pink, demonstrating high levels of mycobacterial growth, while wells with broth alone appeared as blue color, which demonstrated no growth and lack of contamination. The isoniazid containing control wells were pink revealing the clinical isolates were isoniazid resistant. Whilst the extract demonstrated highest activity against AOZ8W-4 strain (MIC 78 μg/ml), it had a moderate activity against both AOA8W-4 and SO38SW-4 strain (MIC 156 μg/ml).

Table 3 Antimycobacterial activity test of Pterolobium stellatum chloroform extract against MDR-TB clinical isolates
Full size table

Activity testing of solvent fractions on standard strains using Resazurin method

As presented in Table 4, n-hexane and aqueous fractions were evaluated in a concentration series of 1000 to 0.977 μg/ml, while ethyl acetate fraction with 200 to 0.195 μg/ml concentrations. The microtiter wells were pink below a concentration of 15.625 μg/ml for the n-hexane fraction, indicating that this fraction was active against the standard strain (MIC = 15.625 μg/ml). By contrast, all wells were pink for the aqueous fraction, suggesting that this fraction was not active against the bacteria within the exposure concentrations used for the experiment. The ethyl acetate fraction was active against M. tuberculosis H37Rv (MIC = 0.195 μg/ml), indicating that this fraction is the most active fraction of P. stellatum chloroform extract (Table 5). As described above, all wells treated with the vehicle were pink, demonstrating no inhibitory role of the vehicle.

Table 4 Test suspension colors obtained from fractions tested against Mycobacterium tuberculosis H37Rv
Full size table
Table 5 Minimum inhibitory concentrations of solvent fractions against Mycobacterium tuberculosis H37Rv
Full size table

Discussion

Current TB therapy consists of treatment with a combination of drugs. This combination therapy causes hepatotoxicity as the major side effect as well as development of drug resistance. To avert toxicity and reduce ineffectiveness of current anti-TB drugs, medicinal plants are considered as potential anti-tuberculosis agents that can be used in combination with the standard anti-tuberculosis drugs or alone [20]. In this study, antimycobacterial activity of crude extract of O. integrifolia, V. amygdalina, C. edulis, P. americana, P. stellatum and as well as fractions of the most active crude extract was investigated.

From the aerial parts of O. integrifolia otostegin A, otostegin B, 15-epi-otostegin B, preleoheterin, leoheterin, and related compounds, including leopersin C, 15-epi-leopersin C, ballonigrin, vulgarol, and 8-O-acetylharpagide were isolated and reported. In addition, the essential oil and chloroform extract of air-dried leaves of O. integrifolia constitute monoterpenes, sesquiterpenes, diterpenes and their derivatives were identified [21]. Phytochemical screening study report indicated that saponins, glycosides and tannins, which are known to be bioactive purgative principles were present in V. amygdalina extract. Flavonoids are also present in the plant that possess antioxidant activity and may play a beneficial role in cancer prevention and offer some protection against diabetes and atherosclerosis [22].

The chemical compositions of C. edulis have extensively been reported. Roots contain an active ingredient, carissin that may prove useful in the treatment of cancer. The twigs contain quebrachytol and cardioglycosides that are useful as an anthelmintic against tapeworm [23] and the roots contain lupeol (has antiviral activity), oleuropein, carissol and β-amyrin [24]. Major chemical constituents of P. americana include the following: the leaf contains volatile oil, flavonoids and coumarins; the fruit contains sesquiterpenes and carbohydrates; the seed contains fixed oil consisting of vitamins A, D3, alpha tocopherol and cholesterol. The fruit is a significant source of protein, monounsaturated fatty acids, vitamin A, thiamin, riboflavin, niacin, vitamin B6, vitamin C, vitamin E, folate, vitamin K, pantothenic acid, magnesium, manganese, phosphorus and the amino acids tryptophan, valine, tyrosine, threonine, phenylalanine and methionine [25]. Chemical classes present in P. stellatum 80% root extract are terpenoids, saponins and tannins and had antibacterial activity as reported by previous study.

The result of the study revealed that three of the experimental plants had significant anti-tuberculosis activity. The activity was seen with chloroform and methanol extracts of P. stellatum and O. integrifolia as well as with methanol and acetone extracts of P. americana. In addition, fractions from the most active plant, P. stellatum had demonstrated promising antimycobacterial activity [8].

MICs of all experimental plant extracts and solvent fractions of the most active plant extract were determined by CFU method and microplate resazurin assay method. As evidenced from Tables 2 and 3, P. stellatum chloroform extract was endowed with lower MIC by CFU method than by microplate resazurin assay method, although test organisms were different. It has been reported that the MIC exhibited by a compound/extract depends on the technique used for determination. MICs obtained in a liquid medium are lower than that obtained from a solid medium, as the drug has to diffuse through the matrix in the solid medium in order to exert activity [20].

MIC of P. stellatum chloroform extract was evaluated using CFU and Resazurin indicator method. The finding in the later method revealed that the MICs were 0.078, 0.156 and 0.156 mg/ml against AOZ8W-4, AOA8W-4 and SO38SW-4 MDR-TB clinical isolates, respectively. However, the extract had lower MIC (0.039 mg/ml) against the standard strain. The difference in MICs might be ascribed to the difference in susceptibility of the standard strain and MDR-TB clinical isolates towards the extract. Furthermore, this apparent difference might be attributed to more favorable growth conditions provided by agar culture medium to extract-treated bacilli in colony count method or the drug susceptible standard strain and the drug resistant strain might have different growth conditions. Another cause for the different MICs of P. stellatum chloroform extract could be the slight difference in sensitivities of colony count method and resazurin indicator method as reported by Taneja and Tyagi [26]. According to this study, Resazurin indicator assay was noted to be superior to the colony count assay in that it distinguished between metabolically active dormant bacteria and non-viable organisms, unlike the colony count assay that could not differentiate between these two populations.

In this study, P. stellatum chloroform extract showed promising activity against M. tuberculosis H37Rv and AOZ8W-4, with complete inhibition at 0.039 mg/ml and 0.078 mg/ml, respectively. These values are within the range stated by the Clinical and Laboratory Standards Institute [27]. In addition, the MDR-TB clinical isolates were resistant to isoniazid, while this plant was active against the clinical isolates of MDR-TB, possibly suggesting that the plant could have an obvious advantage over the standard drug. Moreover, the activity displayed by this extract makes the plant to be a promising plant according to Tosun et al. [28], which states that compounds with an MIC of less than 10 μg/ml, and ideally less than 2 μg/ml could have a potential for further investigation.

There is sparse data in the literature about the antimycobacterial activity of P. stellatum, making comparison a bit difficult. A study reported that 80% ethanol leaf extract of the plant had shown activity (MIC = 250 mg/ml) on M. tuberculosis H37Rv [9]. This value is much higher than the value obtained in this study, possibly indicating that non-polar constituents might be more responsible for the observed antitubercular activity. Efforts made to compare activity of the chloroform extract of P. stellatum with other plants showed either better or comparable activity. Activity was better compared to stem bark extract of Anogeissus leiocarpus [13] and comparable to that of the chloroform leaf extract of Byrsonima fagifolia [29].

Although 80% methanol extract of P. stellatum (MIC = 0.312 mg/ml), P. americana (MIC = 2.5 mg/ml) and O. integrifolia (MIC = 0.312 mg/ml) as well as chloroform extract of O. integrifolia (MIC = 0.312 mg/ml) and acetone extract of P. americana (MIC = 1.25 mg/ml) had significantly higher activity than vehicle-treated controls, they failed to exhibit promising activity according to Tosun [30] or Sánchez [31]. The MICs in this finding are lower/equal than a study done on methanol extract of Pelargonium sidoides (MIC = 5000 μg/ml) as well as methanol extract of Capparis brassi, Entada africana and Combretum species (MIC = 1250 μg/ml each) against M. tuberculosis H37Rv [12]. However, the MICs were higher than that of chloroform extract of Byrsonima fagifolia (MIC = 62.5 μg/ml) [29]. This difference might be imputed to the fact that different plant species may contain different active constituents at varying amount and/or different in vitro methods were used.

Previous studies reported several plants with promising anti-tubercular activity [13, 29–33]. Studies had mostly reported activity in the plant families of Asteraceae, Lamiaceae, Fabaceae and Apiaceae, among others [34]. It is noticeable from the present study that plants exhibiting activity belong to Fabaceae, Lamiaceae and Lauraceae families, which is in agreement with the plant families previously reported [34].

Antimycobacterial activity evaluation revealed that P. stellatum chloroform root extract to have a better activity and further fractionation was pursued and activity of the fractions was evaluated. Accordingly, the ethyl acetate fraction was found to be the most active fraction, based on MIC values (0.195 μg/ml), which indicated that antimycobacterial constituents were contained in this fraction. Further work is underway to isolate and characterize active principles from this fraction.

Conclusion

The results of this study showed that P. stellatum, O. integrifolia and P. americana are endowed with a significant antimycobacterial activity. However, it seems that the potential to develop new compounds against both drug susceptible as well as MDR-TB rests with P. stellatum. The ethyl acetate fraction of this plant was the most active solvent fraction and further study is underway with this fraction. Although the present study provided evidence for the traditional use of some of the plants for treatment of TB, the evidence did not support the use of V. amygdalina and C. edulis for the same.

Abbreviations

ADC:

Albumin dextrose complex

AIDS:

Acquired immune deficiency syndrome

ANOVA:

Analysis of variance

CFU:

Colony forming unit

DMSO:

Dimethyl sulphoxide

HIV:

Human immunodeficiency virus

MDR-TB:

Multidrug resistant tuberculosis

MIC:

Minimum inhibitory concentration

TB:

Tuberculosis

WHO:

World Health Organization

XDR-TB:

Extremely drug resistant tuberculosis

References

  1. Brudey K, Driscoll JR, Rigouts L. Mycobacterium Tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification. BMC Microbiol. 2006;6:23.

    Article  PubMed  PubMed Central  Google Scholar 

  2. WHO. World TB report 2001. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2002.

    Google Scholar 

  3. WHO. Global tuberculosis report 2014. Geneva: World Health Organization; 2015.

    Google Scholar 

  4. Mariita RM, Okemo PO, Orodho JA, Kirimuhuzya C, Otieno JN, Magadula JJ. Efficacy of 13 medicinal plants used by indigenous communities around Lake Victoria, Kenya, against tuberculosis, diarrhoea causing bacteria and Candida Albicans. IJPT. 2010;2(3):771–91.

    Google Scholar 

  5. Raiz M, Zia-Ul Haq M, Saad B. Anthocyanins and human health: Biomolecular and Therapeutic Aspects. Switzerland: Springer International Publishing AG; 2016.

  6. Hamisi MM, Vitus AN, Andrew M. Anti‐TB Natural Products in Tanzanian Medicinal Plants. 2009. http://www.nimr.or.tz/ Anti‐TB Natural Products in Tanzanian Medicinal Plants. Accessed 31 Oct 2015.

  7. Mitscher LA, Baker WR. A search for novel chemotherapy against tuberculosis amongst natural products. Pure Appl Chem. 1998;70(2):365–271.

    Article  CAS  Google Scholar 

  8. Andualem G, Umar S, Getnet F, Tekewe A, Alemayehu H, Kebede N. Antimicrobial and phytochemical screening of methanol extracts of three medicinal plants in Ethiopia. Adv Biol Res. 2014;8(3):101–6.

    Google Scholar 

  9. Balcha E, Mengiste B, Gebrelibanos M, Worku I, Ameni G. Evaluation of In-vitro Anti-mycobacterial Activity of Selected Medicinal Plants in Mekelle, Ethiopia. World Appl Sci J. 2014;31(6):1217–20.

    Google Scholar 

  10. Endale A, Bisrat D, Animut A, Bucar F, Asres K. In vivo antimalarial activity of a Labdane Diterpenoid from the leaves of Otostegia integrifolia benth. Phytother Res. 2013. doi:10.1002/ptr.4948.

    PubMed  Google Scholar 

  11. Getahun A. Some Common Medicinal and Poisonous Plants Used in Ethiopian Folk Medicine. 1976. http://www.mrc.ac.za/. Accessed 14 Dec 2014.

  12. Institute for Laboratory Animal Research (ILAR). Guide for the care and use of laboratory animals. Washington: National Academy Press; 2001.

    Google Scholar 

  13. Mann A, Amupitan JO, Oyewale AO, Okogun JI, Ibrahim K, Oladosu P, Lawson L, Olajide I, Nnamdi A. Evaluation of in vitro antimycobacterial activity of Nigerian plants used for treatment of respiratory diseases. Afr J Biotechnol. 2008;7(11):1630–6.

    Article  Google Scholar 

  14. OECD guideline for testing of chemicals. Acute Oral Toxicity– Acute Toxic Class Method. 2001.

  15. Gomez-Flores R, Arzate-Quintana C, Quintanilla-Licea R, Tamez-Guerra P, Tamez-Guerra R, Monreal-Cuevas E, Rodríguez-Padilla C. Antimicrobial Activity of Persea americana Mill (Lauraceae) and Gymnosperma glutinosum (Spreng.) (Asteraceae) leaf extracts and active fractions against Mycobacterium tuberculosis. Am-Euras J Sci Res. 2008;3(2):188–94.

    Google Scholar 

  16. Nvau JB, Oladosu PO, Orishadipe AT. Antimycobacterial evaluation of some medicinal plants used in Plateau State of Nigeria for the Treatment of Tuberculosis. Agric Biol J N Am. 2011;2(9):1270–2.

    Article  Google Scholar 

  17. Xuan L, David P, Jose AA, Begona G, Silva M, Aida D, Elsa A, Maria-Jose UF. Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique. J Ethnopharmacol. 2011;137:114–20.

    Article  Google Scholar 

  18. Patricia CE, Juan MJ, Elvira G, Noemí W, María Y, Maríadel R. Antimycobacterial activity of constituents from Foeniculum Vulgare Var. Dulce Grown in Mexico. Molecules. 2012;17:8471–82.

    Article  Google Scholar 

  19. Deepthi R, Junise V, Shibin SS, Rajesh S. Isolation, identification and Antimycobacterial evaluation of Piperine from Piper longu. Pharm Lett. 2012;4(3):863–8.

    Google Scholar 

  20. Nair SS, Pharande RR, Bannalikar AS, Mukne AP. In vitro anti-mycobacterial activity of acetone extract of glycyrrhiza glabra. J Pharm Pharmacogn Res. 2015;3(4):81.

    Google Scholar 

  21. Tesso H, König A. Terpenes from Otostegia integrifolia. Phytochemistry. 2004;65:2057–62.

    Article  CAS  PubMed  Google Scholar 

  22. Yusuf AB, Umar IA, Nok AJ. Effects of methanol extract of vernonia amygdalina leaf on survival and some biochemical parameters in acute trypanosoma brucei infection. Afr J Biochem Res. 2012;6(12):150–8.

    Google Scholar 

  23. Orwa C, Mutua A, Kindt R, Jamnadass R, Simons A. Agroforestree Database: a Tree Reference and Selection Guide Version 4.0. 2009. http://www.kemri.org/. Accessed 29 Oct 2015.

  24. Tolo MF, Rukung WG, Muli WF, Ochora MJ, Irungu NB, Muthaura NC, Wanjiku KC, Mungai MG, Quang N, Hashimoto K, Asakawa Y. The antiviral activity of compounds isolated from Kenyan Carissa edulis (Forssk.) vahl. JMPR. 2010;4(15):1517–22.

    CAS  Google Scholar 

  25. Yukes JE, Balick MJ, editors. Dominican medicinal plants: a guide for health care providers. 2nd ed. New York: The New York Botanical Garden; 2010.

    Google Scholar 

  26. Taneja NK, Tyagi JS. Resazurin reduction assays for screening of anti- tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother. 2007;60:288–93.

    Article  CAS  PubMed  Google Scholar 

  27. CLSI. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-524. Wayne: Clinical and laboratory standards institute; 2014.

    Google Scholar 

  28. Tosun F, Akyüz Kizilay C, Sener B, Vural M, Palittapongarnpim P. Antimycobacterial screening of some Turkish plants. J Ethnopharmacol. 2004;95:273–5.

    Article  CAS  PubMed  Google Scholar 

  29. Higuchi CT, Pavan FR, Sato DN. Apolar compounds with antitubercular activity. Compl Alt Med. 2008;1:5.

    Google Scholar 

  30. Sánchez JG, Kouznetsov VV. Anti-mycobacterial susceptibility testing methods for natural products research. Braz J Microbiol. 2010;41:270–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Billo M, Cabalion P, Waikredre J, Fourneau C, Bouttier S, Hocquemiller R, Fournet A. Screening of some New Caledonian and Vanuatu medicinal plants for anti-mycobacterial activity. J Ethnopharmacol. 2005;96(3):569–75.

    Article  CAS  PubMed  Google Scholar 

  32. Jiménez-Arellanes A, Meckes M, Torres J, Luna-Herrera J. Anti-mycobacterial Triterpenoids from Lantana hispida (Verbenaceae). J Ethnopharmacol. 2007;111:202–5.

    Article  PubMed  Google Scholar 

  33. Newton SM, Lau C, Gurcha SS, Besra GS, Wright CW. The evaluation of forty-three plant species for In vitro Antimycobacterial activities; isolation of active constituents from Psoralea corylifolia and Sanguinaria canadensis. J Ethnopharmacol. 2002;79:57–67.

    Article  PubMed  Google Scholar 

  34. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of Antimycobacterial agents. J Ethnopharmacol. 2007;110:200–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are thankful to Addis Ababa University, University of Gondar and Armauer Hanson Research Institute for funding the study.

Funding

The sources of funding for this research are as follows:

The source of fund for the design of the study and plant sample collection was Addis Ababa University where as Armauer Hanson Research Institute provided lab space and consumables. Analysis and interpretation of data and manuscript writing was funded by University of Gondar.

Availability of data and materials

Almost all the materials and data of our study are included in the manuscript. A few of the material and data will be available to other researchers upon request.

Authors’ contributions

All authors have made substantial contributions in the research, preparation and revision of manuscript. The principal contributor for the conception and design, acquisition, analysis and interpretation of data as well as manuscript writing was Wubayehu Kahaliw (Ph. D). Ephrem Engdawork (Ph. D) and Abreham Aseffa (Ph. D) involved in the design of the study, revising the manuscript critically for important intellectual content. Markos Abebe (Ph. D) and Mekonnen Teferi (DVM, Msc) contributed in data acquisition and in revising manuscript. Each author has participated in the work and has given final approval of the version to be published.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All the experiments were conducted in accordance with internationally accepted laboratory animal use, care and guideline and the study was approved by the School of Pharmacy Ethics Committee (Protocol number was 042/12/pharmacy). Before and during the experiment, mice were allowed free access to standard pellets and water ad libitum.

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, P. O. Box: 196, Gondar, Ethiopia

    Wubayehu Kahaliw

  2. Armauer Hanson Research Institute, P. O. Box: 1005, Addis Ababa, Ethiopia

    Abraham Aseffa, Markos Abebe & Mekonen Teferi

  3. Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P. O. Box: 1176, Addis Ababa, Ethiopia

    Ephrem Engidawork

Authors
  1. Wubayehu Kahaliw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abraham Aseffa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markos Abebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mekonen Teferi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ephrem Engidawork
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wubayehu Kahaliw.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kahaliw, W., Aseffa, A., Abebe, M. et al. Evaluation of the antimycobacterial activity of crude extracts and solvent fractions of selected Ethiopian medicinal plants. BMC Complement Altern Med 17, 143 (2017). https://doi.org/10.1186/s12906-017-1563-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-017-1563-0

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us